Objective
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of human cancers. Therefore, PI3Ks have emerged as important targets for drug discovery and, during 2014, the first PI3K inhibitor was approved by FDA in the US for the treatment of a lymphocytic leukaemia. Nonetheless, our understanding of PI3K-mediated signalling is still poor and only a fraction of the potential therapeutic applications have been addressed so far, leaving a large amount of translational work unexplored. Europe features a set of top quality research institutions and pharmaceutical companies focused on PI3K studies but their activities have been so far scattered. This proposal fills this gap by providing a multidisciplinary network (biochemistry, mouse studies, disease models, drug development, software development) and an unprecedented training opportunity from the bench to the bedside (from pre-clinical discoveries to clinical trials), through cutting edge molecular biology, drug discovery and clinical trial organization. The proposal is aimed at training young investigators in deep understanding of the different PI3K isoforms in distinct tissues and to translate this knowledge into a new generation of PI3K inhibitors, treatment modalities and into identify new uses for existing PI3K inhibitors.
Field of science
- /natural sciences/biological sciences/molecular biology
- /medical and health sciences/clinical medicine/endocrinology/diabetes
- /natural sciences/computer and information sciences/software/software development
- /medical and health sciences/health sciences/inflammatory diseases
- /humanities/philosophy, ethics and religion/ethics/ethical principles
- /medical and health sciences/clinical medicine/cancer
- /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases
Programme(s)
Call for proposal
H2020-MSCA-ITN-2015
See other projects for this call
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
08908 L'hospitalet De Llobregat
Spain
Participants (10)
WC1E 6BT London
12489 Berlin
CB22 3AT Cambridge
75654 Paris
67404 Illkirch Graffenstaden
08035 Barcelona
10124 Torino
4051 Basel
85716 Unterschleissheim
CB2 1TN Cambridge
Partners (2)
Barcelona
Illkirch-graffenstaden
